Crescendo Biologics Limited
Crescendo Biologics is a Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.
|Telephone:||+44 (0)1223 497 140|
|Address:||Meditrina 260, Babraham Research Campus, Babraham|
|Membership type:||Corporate 21-50 (£500+VAT pa)|
Next Generation Antibody Therapeutics
The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Crescendo brings together two technologies invented by scientists at the Babraham Institute in Cambridge: a novel transgenic technology for in vivo generation of human heavy chain antibodies (and thereby VH fragments), and a ribosome display platform for affinity optimisation in vitro. These are being developed to generate a combined platform for discovery and optimisation of human VH-based therapeutics that addresses key issues with existing in vitro or non-human in vivo platforms.
For more information, see www.crescendobiologics.com
Crescendo Biologics Ltd, the developer of targeted T-cell engagers, announced that it has achieved another technical milestone in its collaboration with Takeda Pharmaceutical Company Limited.
16 August 2018Read in full
Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, and Cambridge-based Crescendo Biologics Ltd, the developer of multi-functional biologics, announced today an exclusive, worldwide licensing agreement under which Zai Lab will develop, commercialise, and manufacture a topical, innovative antibody VH domain therapeutic for potential application in inflammatory indications.
30 May 2018Read in full
Crescendo Biologics Ltd, the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced that it has completed a $70 million (€57 million) Series B financing. This is the largest disclosed Series B biotech financing in Europe this year.
1 May 2018Read in full
A new collaboration between Crescendo Biologics and Takeda aims to generate tumor targeting drug conjugates and immuno-oncology therapeutics.
10 October 2016Read in full
Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the launch of the Company’s new drug development strategy.
15 October 2015Read in full
Crescendo Biologics expands ADC Programmes with Innovate UK Funding award: Biomedical Catalyst Award to support development of new therapies to target prostate cancer
27 May 2015Read in full
Nature Biopharma Dealmakers: Humabody Fragments™: small and perfectly formed
9 March 2015Read in full
Crescendo Biologics’ receives further investment from Astellas Venture Management to develop novel Humabody™ Therapeutics targeting immune checkpoint inhibitors.
14 December 2014Read in full